• Diminazene Aceturate: A Context-Dependent Research Probe

  2026-09-25

  Diminazene Aceturate is best interpreted as a context-dependent research probe, not as a single-purpose mechanistic answer. This article examines how to distinguish its trypanocidal use from ACE2-related findings, assess the strength of the evidence, and design more informative experiments.

• SGI-1027 Workflows for DNA Methylation Research

  2026-09-25

  Use SGI-1027 to probe DNMT-dependent methylation and tumor suppressor gene reactivation, while separating growth arrest from actual cell killing. A staged workflow pairs dose and time courses with methylation, expression, protein, and viability readouts so epigenetic effects are not mistaken for general toxicity.

• CCCP and Mitochondrial Image Assay Interpretation

  2026-09-24

  CCCP (carbonyl cyanide m-chlorophenyl hydrazine) disrupts the mitochondrial proton gradient, but its effects should not be confused with a direct readout of mitochondrial shape or disease. Learn how to interpret CCCP perturbations alongside deep-learning analysis of urine-derived stem cells and Alzheimer’s disease research.

• Sodium salicylate for Reliable Cell Assays

  2026-09-24

  Practical guidance for using Sodium salicylate (SKU B2028) in cell viability and signaling experiments, with attention to assay interpretation, solubility, and controls. The article separates product specifications from workflow recommendations and clarifies what current cross-domain evidence can—and cannot—support.

• SMAD3 Inhibition Reduces ADAMTS-5 in Early OA

  2026-09-23

  Xiang et al. report that pharmacological SMAD3 inhibition lowers ADAMTS-5 expression in cell and rat models of early osteoarthritis, alongside increased miRNA-140 expression. The findings suggest a candidate regulatory connection between SMAD3, miRNA-140, and cartilage catabolism, while leaving the precise mediation mechanism and later-stage effects unresolved.

• SGI-1027: DNA Methyltransferase Inhibitor Workflow

  2026-09-23

  Build a reproducible SGI-1027 workflow for DNMT inhibition, promoter demethylation, tumor suppressor gene reactivation, and apoptosis studies. The guide connects biochemical assays with Huh7 cancer-cell validation while emphasizing formulation, controls, and interpretation limits.

• Chloramphenicol for Plasmid Selection Workflows

  2026-09-22

  Chloramphenicol enables tunable plasmid selection while providing a practical readout of plasmid maintenance, host background, and resistance-marker behavior. This workflow guide connects routine cloning assays with recent evidence on carbapenemase-gene localization and transfer, without treating research selection as a clinical susceptibility test.

• JC-1 for Mitochondrial Redox-State Research

  2026-09-22

  JC-1 converts mitochondrial membrane potential into a ratiometric fluorescent readout that can sharpen apoptosis detection and mitochondrial dysfunction research. This article explains how to use the probe alongside ferroptosis-focused evidence from pulmonary fibrosis research without confusing membrane depolarization with a complete diagnosis of cell death.

• AG-120 (Ivosidenib): Assay Strategy for IDH1

  2026-09-21

  AG-120 (Ivosidenib) is more than a mutant IDH1 inhibitor: it is a mechanistic probe for linking 2-hydroxyglutarate reduction with leukemia-cell differentiation. This guide presents an assay framework that separates direct pharmacodynamic effects from metabolic adaptation and CD44-associated resistance.

• Chloramphenicol: Mechanism & Plasmid Selection

  2026-09-21

  Chloramphenicol is a bacterial 50S ribosomal inhibitor used in plasmid selection assays and molecular biology research. The A2512 product is defined by its chemical identity, documented solvent compatibility, storage guidance, and reported purity, while the cited CREC study shows why selection experiments must remain distinct from clinical resistance epidemiology.

• Dacomitinib (PF-00299804) Pan-HER Research Guide

  2026-09-20

  Dacomitinib, also designated PF-00299804, is an irreversible ErbB-family kinase inhibitor with reported activity against EGFR, HER2, and HER4. Its research profile supports studies of receptor-signaling blockade, apoptosis induction in cancer cells, cell cycle G0–G1 arrest, and non-small-cell lung carcinoma treatment models.

• EZ Cap™ CBEmax mRNA (m1Ψ) Workflow

  2026-09-19

  Build a controlled cytosine base-editing workflow around transient mRNA delivery, guide selection, and orthogonal validation. The approach translates the BLG stop-codon case in cattle into practical assay choices for cell and embryo genome-editing research.

• Chloramphenicol as a Selection-Pressure Control

  2026-09-18

  Chloramphenicol is more than a plasmid-selection antibiotic: it can serve as a carefully controlled experimental variable when interpreting plasmid maintenance, gene mobility, and resistance assays. This guide connects the compound’s ribosomal mechanism with the 2025 CREC study while defining what chloramphenicol selection can—and cannot—prove.

• TaqI Restriction Endonuclease Protocol

  2026-09-18

  TaqI Restriction Endonuclease provides rapid, sequence-specific cleavage of plasmid DNA, PCR products, and genomic DNA when a TCG A recognition site is present. It is intended for research workflows such as cloning and fragment analysis, not for diagnostic, clinical, or medical use.

• DOTAP Workflows for Nucleic Acid Delivery

  2026-09-17

  Build reproducible DNA, RNA, and antisense oligonucleotide delivery workflows with DOTAP while controlling formulation, exposure, and cell-specific toxicity. The approach also provides a practical perturbation platform for testing immune-metabolic hypotheses inspired by recent nano-zoledronate research.

3695 records 1/247 page Next 12345 下5页 Last page